Abstract：
BACKGROUND: The prevalence of Barrett\'s esophagus (BE) in France is unknown. However, the management of dysplastic BE in expert centers is recommended and reduces the risk of developing invasive adenocarcinoma. Our aim was to determine the burden of BE patients in the Paris Region.
METHODS: We performed a retrospective study using the data from electronic medical records from the data warehouse of the 39 Greater Paris public hospitals (Entrepôt de données de santé de l\' Assistance Publique- Hôpitaux de Paris) for the year 2018, and used natural language processing to search for occurrences of Barrett\'s esophagus in endoscopy and pathology reports.
RESULTS: we observed a 2.2 % prevalence of Barrett\'s esophagus. Patients with Barrett\'s esophagus were older, more frequently males, with a hiatal hernia, proton pump inhibitor users, and less frequently infected by H. Pylori. Gastro-esophageal reflux symptoms were not more frequently encountered in Barrett\'s patients. Eleven percent of patients with Barrett\'s esophagus had dysplasia or adenocarcinoma.
CONCLUSIONS: Over 200 000 patients with Barrett\'s esophagus are expected in the Paris Region, of which 11 % harbor dysplasia or adenocarcinoma. This data should be taken into account to tailor healthcare offer in France.
METHODS: We performed a retrospective study using the data from electronic medical records from the data warehouse of the 39 Greater Paris public hospitals (Entrepôt de données de santé de l\' Assistance Publique- Hôpitaux de Paris) for the year 2018, and used natural language processing to search for occurrences of Barrett\'s esophagus in endoscopy and pathology reports.
RESULTS: we observed a 2.2 % prevalence of Barrett\'s esophagus. Patients with Barrett\'s esophagus were older, more frequently males, with a hiatal hernia, proton pump inhibitor users, and less frequently infected by H. Pylori. Gastro-esophageal reflux symptoms were not more frequently encountered in Barrett\'s patients. Eleven percent of patients with Barrett\'s esophagus had dysplasia or adenocarcinoma.
CONCLUSIONS: Over 200 000 patients with Barrett\'s esophagus are expected in the Paris Region, of which 11 % harbor dysplasia or adenocarcinoma. This data should be taken into account to tailor healthcare offer in France.
摘要：
背景：法国Barrett食管（BE）的患病率未知。然而,建议在专家中心对发育不良的BE进行治疗,并降低发展为浸润性腺癌的风险.我们的目标是确定巴黎地区BE患者的负担。
方法：我们进行了一项回顾性研究，使用了来自39家大巴黎公立医院数据仓库的电子病历数据（援助公共图书馆-巴黎医院）2018年的数据，并使用自然语言处理在内窥镜检查和病理报告中搜索巴雷特食管的发生。
结果：我们观察到Barrett食管的患病率为2.2%。Barrett食管患者年龄较大,更常见的是男性，有食管裂孔疝,质子泵抑制剂用户，感染H.Pylori的频率较低。Barrett患者的胃食管反流症状并不常见。11%的Barrett食管患者患有发育不良或腺癌。
结论：预计巴黎地区将有超过200,000名Barrett食管患者，其中11%的港湾发育不良或腺癌。在法国定制医疗保健服务时，应考虑这些数据。
方法：我们进行了一项回顾性研究，使用了来自39家大巴黎公立医院数据仓库的电子病历数据（援助公共图书馆-巴黎医院）2018年的数据，并使用自然语言处理在内窥镜检查和病理报告中搜索巴雷特食管的发生。
结果：我们观察到Barrett食管的患病率为2.2%。Barrett食管患者年龄较大,更常见的是男性，有食管裂孔疝,质子泵抑制剂用户，感染H.Pylori的频率较低。Barrett患者的胃食管反流症状并不常见。11%的Barrett食管患者患有发育不良或腺癌。
结论：预计巴黎地区将有超过200,000名Barrett食管患者，其中11%的港湾发育不良或腺癌。在法国定制医疗保健服务时，应考虑这些数据。
